MolDX: Next-Generation Sequencing for Solid Tumors

Medicare coverage is allowed, at MAC discretion under NCD 90.2 Section D, for next-generation sequencing (NGS) clinical laboratory tests—including LDTs and FDA-cleared/approved tests—when used for solid tumor cancer testing. Coverage explicitly excludes hematologic malignancies, circulating tumor DNA (ctDNA) testing, and germline testing in/for patients with cancer.

"Coverage is allowed for clinical laboratory tests using next-generation sequencing (NGS), including lab-developed tests (LDTs) and FDA-cleared or FDA-approved tests, for solid tumor cancer testing ..."

Sign up to see full coverage criteria, indications, and limitations.